RxDoctor Payments Data

Marissa Sansone, MD

Rheumatology · New Haven, CTNPI 1063874063

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 38.0% of the total. 2025 is the largest year on record at $721, more than ten times the $30 reported in 2023. That places this record below the midpoint for rheumatology clinicians in CT, where the typical reported total is $1,253.

$1,325in general payments, 2019–2025

Across 80 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$503
  • Johnson & Johnson$227
  • AbbVie$102
  • E.r. Squibb & Sons, L.L.C.$92
  • Novartis$56
  • Pfizer$54
  • plus $291 from 9 others

What the payments were for

  • Food & beverage$1,24594%
  • Education$806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,325 in reported general payments places this provider in the 50th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$111,136
Medicare patients
220
Services billed
1,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab12$20,045
Celecoxib13$907
MethotrexateMethotrexate Sodium67$905
Prednisone152$833
Hydroxychloroquine Sulfate26$574
Mycophenolate Mofetil12$557
Colchicine13$439
Diclofenac Sodium24$430
Alendronate Sodium31$301
Allopurinol43$263
Gabapentin30$196
Methylprednisolone23$136
Meloxicam20$52
Folic Acid11$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$503$20,04512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 118 rheumatology providers in Connecticut.

Other rheumatology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →